This site is intended for health professionals only

Combination beats COX-2 inhibitor alone

teaser

A controlled trial has found that combining a proton-pump inhibitor(PPI) with a COX-2 inhibitor is more effective in reducing the risk ofgastrointestinal (GI) bleeding in high-risk patients than use of theCOX-2 inhibitor alone.

Patients taking NSAIDs are atincreased risk of GI bleeding and those with a past history of ulcerbleeding are at highest risk. Guidelines based on trial evidencesuggest benefits from using a COX-2 inhibitor or NSAID plus PPI inpatients at higher risk; however, there is limited evidence regardingthe safest option for the highest-risk patients.

Thistrial aimed to determine whether a COX-2 inhibitor plus a PPI wasbetter than the COX-2 inhibitor alone for reducing the risk ofrecurrent bleeding in patients who had previous NSAID-induced bleedingand continued to need an anti-inflammatory analgesic.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Itincluded patients with upper-GI bleeding who were taking a nonselectiveNSAID for arthritis. They were taken off the NSAID, treated for Helicobacter pyloriinfection if appropriate and given a PPI for eight weeks to promoteulcer healing. Eligible patients were those for whom this regimensuccessfully treated any H pylori infectionand healed their ulcer and who continued to require NSAID therapy. Theywere randomised to receive celecoxib 200mg twice-daily plus eitheresomeprazole or placebo daily. Study duration was 12 months andpatients were followed-up at two-month intervals and at 13 months;primary outcome was recurrent ulcer bleeding during treatment and up toa month from the end of treatment.

Of 441 patientsscreened, 273 were randomised and eligible for the intention-to-treatanalysis – 137 to combined treatment and 136 to control (celecoxibalone). Median follow-up was 13 months and treatment compliance wasgood in both groups (>90%). Combination treatment was more effectivethan the control: there were no primary endpoint events in thecombination group vs 12 (8.9%) in the control group (95% CI for thedifference 4.1–13.7, p=0.0004).

The authors conclude thatthe combination of a COX-2 inhibitor plus a PPI is effective inpatients at very high risk of NSAID-induced GI bleeding and should thusbe used in such patients. They suggest that organisations producingguidelines in this area should review their recommendations accordingly.

Lancet 2007;369:1621-6

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x